麻豆传媒

"Is it time to say primary prophylaxis is dead?" one expert asks

Urgent need for organ allocation system reform, researchers say

GLP-1/GIP agonist also improved fibrosis biomarkers, liver fat, and stiffness in phase II trial

Effects may be related to weight loss, not changes in fibrogenesis, expert suggests

iLFT is now an essential, highly utilized tool at one U.K. primary care system

Combo therapies for HDV with drugs other than pegylated interferon would be better, expert says

Persistent viral suppression in most patients, even after 8 years

Early model suggests a way to predict progression-free survival

Pilot trial demonstrates that FMT can boost gut health, prevent serious infections

Phase IIb ENLIVEN trial saw success with various doses of pegozafermin

Public health expert describes pivot to provide medical aid in war-torn Ukraine

At 48 weeks, bulevirtide led to undetectable HDV RNA, normalization of ALT in up to 48%

Investigational drug more likely to resolve severe form of fatty liver disease, improve fibrosis

Noteworthy research from the European Association for the Study of the Liver annual meeting